Site Search

1. 251.
   AMP/assets/File/position-statements/2017/AMPcommentsonDAIA-FINAL.pdf?pass=6

   For example, a recent assessment of over 1,000 gene mutations from cancer panel testing in 111 laboratories showed 98.3% concordance.1 Page 5, beginning line 17: AMP opposes that the draft legislation seeks to widely expand FDA’s jurisdiction to encompass regulation of LDPs, which is a medical service and emphasizes the ongoing involvement of

   https://www.amp.org/AMP/assets/File/position-statements/2017/AMPcommentsonDAIA-F...
2. 252.
   AMP/assets/File/education/MIMP/GenomicAssays.pdf?pass=42

   However, the VAF is affected by many factors including the variance of the assay (often as high as +/-15%), sampling, assay design, and cytogenetic changes at the allele including amplification or loss of heterozygosity (LOH). The VAF should always be interpreted with caution. For additional assistance, please contact the laboratory or the molecular

   https://www.amp.org/AMP/assets/File/education/MIMP/GenomicAssays.pdf?pass=42
3. 253.
   AMP Certificates Explained - Association for Molecular Pathology

   passing post-test score (75% or greater). Upon successful completion of one of AMP’s certificate programs, learners receive a certificate of completion. (See sample certificate below.) Certificate of attendance These certificates are provided to learners who watch one of our webinar offerings. While they do not confer any certification, accreditation or

   https://www.amp.org/education/amp-certificates-explained/
4. 254.
   Tell Congress: Prioritize patients over gene patents - Association for...

   When I started in my field, gene patents were held on some 20% of the human genome. At that time, the patents hampered the ability of the medical and scientific communities to advance research and develop new tests and treatments for conditions such as cancer, muscular dystrophy, Alzheimer’s disease, and heart disease. In addition, they allowed testing

   https://www.amp.org/about/newsroom/amp-blog-content/tell-congress-prioritize-pat...
5. 255.
   AMP/assets/File/position-statements/2015/AMPresponsetoSenatereport-FINAL.pdf?pass=...

   Position%20Statements/AMPComments_FDAMedicalDeviceWorkshop_062410_final.pdf AMP response to report on Innovation for Healthier Americans • FDA should ensure that policies and requirements are consistently applied, and that the scientific evidence and rationale for decisions are communicated effectively to diagnostic test manufacturers. • Communication

   https://www.amp.org/AMP/assets/File/position-statements/2015/AMPresponsetoSenate...
6. 256.
   AMP Clinical Practice Committee Report, 2012

   January that could result in dramatic reductions (8.2%) to health care related programs including the NIH, CDC, and FDA. After the elections, challenges to draft alternatives will be complicated by the fact that the SGR Medicare physician payment fix, Bush tax cuts, the payroll tax, unemployment benefits and a host of other tax breaks are all scheduled to

   https://www.amp.org/AMP/assets/File/committees/reports/2012_CommitteeReports_KLC...
7. 257.
   30 Years of Innovation - Association for Molecular Pathology

   Board celebrates five-year strategic plan 73% implemented in 2.5 years and revises mission statement. AMP Leadership Award renamed Jeffrey A. Kant Leadership Award. AMP becomes a sponsor of the IOM Translating Genomic-Based Research for Health Genomics Roundtable (“IOM Genomics Roundtable”). New logo adopted. AMP becomes a cooperating society of the

   https://www.amp.org/about/who-we-are/30-years-of-innovation/
8. 258.
   AMP/assets/File/committees/reports/2016CommitteeandSubdivisionAnnualReport_000...

   Schedule (CLFS) and receive more than 50% of their Medicare revenues from laboratory and physician services during a collection period. The first round of data reporting will begin in 2017 with initial reports due to CMS by March 31, 2017. Details on registration and reporting procedures have begun to emerge from CMS. EAC continues to notify and educate

   https://www.amp.org/AMP/assets/File/committees/reports/2016CommitteeandSubdivisi...
9. 259.
   Press Releases - Association for Molecular Pathology

   June 13, 2012 AMP Receives 40% Increase in Abstract Submissions The record-breaking number of abstract submissions for the AMP 2012 Annual Meeting on Genomic Medicine is consistent with the increased number of exhibiting companies and anticipated number of attendees. Continue Reading May 22, 2012 AMP Developing a CPT Coding Proposal for Next Generation

   https://www.amp.org/about/newsroom/press-releases/
10. 260.
    AMP/assets/File/advocacy/FDAcommentsonLDTguidance-FINAL.pdf?pass=11

    cancer occur less than 1% of the time. For example, while lung adenocarcinomas have a rather high incidence, some targetable subtypes are rare and these subtypes should be considered rare and eligible for any rare disease exemption. For these reasons, AMP proposes that a test should be classified as a rare disease LDP if a test is intended to test a variant

    https://www.amp.org/AMP/assets/File/advocacy/FDAcommentsonLDTguidance-FINAL.pdf?...